Search

Cutting-edge practice in glaucoma care: what, how and why?

More effective treatments and drug delivery modalities, implantable minimally invasive glaucoma surgical (MIGS) devices, as well as accelerating clinical research programmes, will transform the surgical and clinical management of glaucoma in the near future. There is also an ever-greater emphasis...

Contemporary glaucoma therapy: spoilt for choice

The goal of glaucoma management is to prevent visual loss and disease progression in the patient’s lifetime through effective lowering of intraocular pressure (IOP), the primary modifiable risk factor in glaucoma. Sustained and consistent IOP reduction is key to halting...

COVID-19 and Charles Bonnet Syndrome

As COVID-19 rips through the country, it is – of course – imperative that we stay at home to try and prevent the virus spreading through the whole community. We are all aware of the need to take special care...

Herpes zoster ophthalmicus: the essentials

Herpes zoster, also referred to as shingles, is a common infection most typically caused by the reactivation of varicella zoster virus that lies dormant (sometime for decades) in the dorsal root nerve ganglion following primary chickenpox infection [1]. In 10-20%...

Sensitive cilia – eyelashes in health and disease

In health our eyelashes protect the eyes, but in disease they can disfigure, impair quality of life and threaten vision. In this review the authors discuss aspects of lashes that are relevant to all professionals working near the eyes and...

My Top Five: Ophthalmology TikTok accounts, educating and entertaining both the public and trainees

In the modern world, our electronic devices have now become an extension of ourselves, with our reliance and use of them of comparable importance to an arm or a leg. The importance of electronic devices can also be seen in...

Broadening of treatment options for potentially blinding retinal conditions

Rod McNeil provides an update on a promising bispecific antibody recently approved for treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO) and considers emerging developments in biosimilars to established anti-vascular endothelial growth factor (anti-VEGF) therapies, including...

My top five: A foundation doctor’s top five misconceptions about ophthalmology

Choosing a specialty is challenging. As a foundation doctor, it often feels as if this choice is based solely on fleeting experiences. Compared to other specialties, there is relatively little exposure to ophthalmology during either medical school or foundation years....

The All Eyes Foundation

At its core, All Eyes Foundation (AEF) wishes to help bring vision back to Iraq, and it intends to do this through ophthalmic subspecialty training, mentoring and infrastructure development. Based in Najaf, just over 100 miles south of Baghdad, the...

Danger Zone: Miles Hilton-Barber

“Life is either a daring adventure, or nothing at all” – Helen Keller, deafblind American author, activist, and disability rights advocate I have always had a thirst for adventure, even if it has been predominantly from the comfort of my...

In conversation with Robert MacLaren

Professor Robert MacLaren gave the Keeler Lecture at the Royal College of Ophthalmologists Annual Meeting in May 2019 on gene therapy for retinitis pigmentosa. We caught up with him afterwards to find out more. What are the key messages of...

In conversation with Imran Rahman (CHEC)

Imran Rahman, CEO and Consultant Ophthalmologist, CHEC, spoke to Chris Henson about tackling the COVID-19 backlog, community-based support for the NHS, and the digitisation of healthcare. Without major intervention, will we ever see an end to the COVID-19-induced NHS backlog,...